Pemigatinib was the first FGFR2 inhibitor approved by the Food and Drug Administration for the treatment of CCA with FGFR2 fusion/rearrangement positivity and is a selective and potent oral competitive inhibitor of FGFR1, FGFR2, and FGFR3 [140]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.